Compare PPBT & UGRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PPBT | UGRO |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.3M | 13.2M |
| IPO Year | 2014 | 2018 |
| Metric | PPBT | UGRO |
|---|---|---|
| Price | $4.11 | $19.23 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $30.00 | N/A |
| AVG Volume (30 Days) | 9.0K | ★ 10.3M |
| Earning Date | 05-20-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $40,008,850.00 |
| Revenue This Year | N/A | $98.41 |
| Revenue Next Year | N/A | $23.34 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.41 | $0.11 |
| 52 Week High | $5.18 | $39.68 |
| Indicator | PPBT | UGRO |
|---|---|---|
| Relative Strength Index (RSI) | 62.28 | 61.93 |
| Support Level | $0.57 | $0.71 |
| Resistance Level | $5.18 | $39.68 |
| Average True Range (ATR) | 0.34 | 6.81 |
| MACD | -0.11 | 1.28 |
| Stochastic Oscillator | 72.85 | 44.90 |
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
Urban-gro Inc operated as an integrated professional services and design-build firm offering architectural, engineering, and construction management solutions to the CEA, industrial, healthcare, and other commercial sectors. The company generated revenue by billing employees time on client projects and provided architectural, engineering, systems procurement and integration, and construction design-build solutions with a single point of accountability. For CEA clients, it developed indoor cultivation facilities for specialty crops, including cannabis and produce such as leafy greens, vegetables, herbs, and berries. Its segments included Equipment Systems (commercial horticulture equipment), Services (design-build services), and Construction Design-Build (general contracting).